Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model
Background. Peritoneal carcinomatosis (PC) accompanied with ascites formation causes several distressing symptoms, resulting in poor quality of life. Methods. Twenty BALB/c nude mice generated by direct orthotopic injection of human pancreatic cancer PANC-1 cells were randomized to receive either a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2013/814054 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550652908142592 |
|---|---|
| author | Ming-Jen Chen Tsang-En Wang Shu-Jung Tsai Ching-Chung Lin Chia-Yuan Liu Horng-Yuan Wang Shou-Chuan Shih Yu-Jen Chen |
| author_facet | Ming-Jen Chen Tsang-En Wang Shu-Jung Tsai Ching-Chung Lin Chia-Yuan Liu Horng-Yuan Wang Shou-Chuan Shih Yu-Jen Chen |
| author_sort | Ming-Jen Chen |
| collection | DOAJ |
| description | Background. Peritoneal carcinomatosis (PC) accompanied with ascites formation causes several distressing symptoms, resulting in poor quality of life. Methods. Twenty BALB/c nude mice generated by direct orthotopic injection of human pancreatic cancer PANC-1 cells were randomized to receive either a stock laboratory diet or a stock diet supplemented with glutamine. Half of the mice were sacrificed at day 76 to measure the amount of ascitic fluid and pancreatic tumor volume. The remaining mice were subject to survival analysis. Serum albumin levels were estimated every 2 weeks. Results. At day 76, the average amount of ascitic fluid measured in the control group was 1.2±0.3 mL compared to 0.5±0.5 mL from the glutamine-supplemented mice (P=0.045). The volume of pancreatic tumor was 2.60±0.8 cm3 in the control group and 1.98±1.3 cm3 in glutamine-supplemented mice (P=0.39). The mean survival time of glutamine-supplemented mice was prolonged from 87±4 to 101±2 days (P=0.0024). Mean serum albumin levels were higher in the glutamine-supplemented group. Conclusions. This preclinical study showed that oral supplementation of glutamine may provide ascites-reducing activity in pancreatic cancer patients with PC, via a cell-mediated immunity-independent mechanism. |
| format | Article |
| id | doaj-art-bcf96e77ab334593807461e14e96931c |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-bcf96e77ab334593807461e14e96931c2025-02-03T06:06:12ZengWileyGastroenterology Research and Practice1687-61211687-630X2013-01-01201310.1155/2013/814054814054Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse ModelMing-Jen Chen0Tsang-En Wang1Shu-Jung Tsai2Ching-Chung Lin3Chia-Yuan Liu4Horng-Yuan Wang5Shou-Chuan Shih6Yu-Jen Chen7Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, TaiwanMackay Medical College, New Taipei, TaiwanBackground. Peritoneal carcinomatosis (PC) accompanied with ascites formation causes several distressing symptoms, resulting in poor quality of life. Methods. Twenty BALB/c nude mice generated by direct orthotopic injection of human pancreatic cancer PANC-1 cells were randomized to receive either a stock laboratory diet or a stock diet supplemented with glutamine. Half of the mice were sacrificed at day 76 to measure the amount of ascitic fluid and pancreatic tumor volume. The remaining mice were subject to survival analysis. Serum albumin levels were estimated every 2 weeks. Results. At day 76, the average amount of ascitic fluid measured in the control group was 1.2±0.3 mL compared to 0.5±0.5 mL from the glutamine-supplemented mice (P=0.045). The volume of pancreatic tumor was 2.60±0.8 cm3 in the control group and 1.98±1.3 cm3 in glutamine-supplemented mice (P=0.39). The mean survival time of glutamine-supplemented mice was prolonged from 87±4 to 101±2 days (P=0.0024). Mean serum albumin levels were higher in the glutamine-supplemented group. Conclusions. This preclinical study showed that oral supplementation of glutamine may provide ascites-reducing activity in pancreatic cancer patients with PC, via a cell-mediated immunity-independent mechanism.http://dx.doi.org/10.1155/2013/814054 |
| spellingShingle | Ming-Jen Chen Tsang-En Wang Shu-Jung Tsai Ching-Chung Lin Chia-Yuan Liu Horng-Yuan Wang Shou-Chuan Shih Yu-Jen Chen Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model Gastroenterology Research and Practice |
| title | Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model |
| title_full | Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model |
| title_fullStr | Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model |
| title_full_unstemmed | Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model |
| title_short | Oral Glutamine Supplement Inhibits Ascites Formation in Peritoneal Carcinomatosis Mouse Model |
| title_sort | oral glutamine supplement inhibits ascites formation in peritoneal carcinomatosis mouse model |
| url | http://dx.doi.org/10.1155/2013/814054 |
| work_keys_str_mv | AT mingjenchen oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT tsangenwang oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT shujungtsai oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT chingchunglin oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT chiayuanliu oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT horngyuanwang oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT shouchuanshih oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel AT yujenchen oralglutaminesupplementinhibitsascitesformationinperitonealcarcinomatosismousemodel |